Page last updated: 2024-11-11

4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9893715
CHEMBL ID1743599
CHEBI ID50016
SCHEMBL ID15753414
MeSH IDM0388148

Synonyms (26)

Synonym
gsao
s-{2-[4-(dihydroxyarsino)phenylamino]-2-oxoethyl}-glutathione
4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide
l-gamma-glutamyl-s-(2-{[4-(dihydroxyarsino)phenyl]amino}-2-oxoethyl)-l-cysteinylglycine
CHEBI:50016 ,
CHEMBL1743599
4-(n-(s-glutathionylacetyl)amino) phenylarsonous acid
SCHEMBL15753414
glycine, l-.gamma.-glutamyl-s-(2-((4-(hydroxyarsinyl)phenyl)amino)-2-oxoethyl)-l-cysteinyl-
1271726-51-2
J2.673.618H ,
334756-34-2
4-(n-(s-glutathionylacetyl)amino)phenylarsonous acid
glycine, l-gamma-glutamyl-s-(2-((4-(hydroxyarsinyl)phenyl)amino)-2-oxoethyl)-l-cysteinyl-
DSA0237V7T ,
p-gsao
unii-dsa0237v7t
glutathione arsenoxide
(s)-2-amino-5-(((r)-3-((2-((4-(dihydroxyarsaneyl)phenyl)amino)-2-oxoethyl)thio)-1-((carboxymethyl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid
Q27121712
(2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-[2-(4-dihydroxyarsanylanilino)-2-oxoethyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
n5-((r)-1-((carboxymethyl)amino)-3-((2-((4-(dihydroxyarsanyl)phenyl)amino)-2-oxoethyl)thio)-1-oxopropan-2-yl)-l-glutamine
HY-130588
CS-0109307
DTXSID901047773
AKOS040748433
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glutathione derivativeAny organonitrogen compound derived from the Glu-Cys-Gly tripeptide glutathione.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID470757Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471041Antiproliferative activity against mouse bEND.3 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID470759Antiproliferative activity against mouse LLC cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471042Antiproliferative activity against HMEC1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471038Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID470755Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471040Antiproliferative activity against MDCK2 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471068Induction of rat mitochondrial swelling assessed as decrease in light scattering2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471039Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID470758Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID470756Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
AID471048Antiproliferative activity against BAEC after 72 hrs by MTT assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (52.63)29.6817
2010's9 (47.37)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (10.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]